Shots:
- The CHMP has recommended AVT03, a biosimilar version of Amgen’s Prolia & Xgeva (denosumab) for the treatment of bone & skeletal disorders
- STADA & Dr. Reddy’s have semi-exclusive commercial rights to AVT03 in the EU, incl. Switzerland & the UK, leading to STADA marketing it as Kefdensis (Prolia; 60mg/mL PFS) & Zvogra (Xgeva; 70mg/mL single-use vial), while Dr. Reddy’s will offer Acvybra (60mg/mL PFS) & Xbonzy (70mg/mL vial)
- Denosumab is a mAb that works by targeting Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), which regulates bone metabolism & osteoclast formation
Ref: Alvotech | Image: Alvotech| Press Release
Related News:- Alvotech and Advanz Pharma Receive the EC’s Approval for Mynzepli (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
